John Sculley, the former CEO of Apple (AAPL) and Pepsi (PEP), is now investing in several potential game-changing private companies that he expects could go public or be acquired by public companies. Sculley recently wrote the book ‘Moonshot!’ which examines strategies that executives can use to build transformative businesses. One of Sculley’s investments is in Zeta Interactive, a firm he co-founded with his friend David Steinberg. Sculley said Zeta Interactive is one of the largest big data marketing analytic companies in the world. ‘We grew about 100% top line, we’re very profitable, and we’re well-positioned to go public probably in 2016,’ he said. Another company Sculley is involved with is MDLIVE, a telehealth firm that connects patients with doctors via a phone or Internet video around the clock for nonemergency situations. ‘This is a company that I think has the potential to become a unicorn, meaning more than a billion dollar valuation, ‘ Sculley explained. He added that MDLIVE has a close partnership with Walgreens (WAG), and has also partnered with over 800 hospitals to provide telehealth services. Sculley is also chairman of a company in Florida called PDQ, a casual dining chain that was founded by the founders of Outback Steakhouse (BLMN). Sculley said PDQ will be a public company someday. ‘We’re just having incredible success with very nutritious foods, no red meats, remember these are the Outback Steakhouse guys, now it’s all chicken. Everything is fresh, every day,’ he said.

More from Video

Shark Tank Star Kevin O'Leary Reveals Why Stocks Haven't Corrected Recently

Shark Tank Star Kevin O'Leary Reveals Why Stocks Haven't Corrected Recently

Podcast: How Exchange Traded Funds Can Obliterate a Stock Sector

Podcast: How Exchange Traded Funds Can Obliterate a Stock Sector

Inside the Next 60 Years for IHOB (aka IHOP)

Inside the Next 60 Years for IHOB (aka IHOP)

Jerome Powell's Testimony Isn't Changing This Strategist's 3,000 S&P 500 Target

Jerome Powell's Testimony Isn't Changing This Strategist's 3,000 S&P 500 Target

Jim Cramer on Johnson & Johnson's Pharmaceuticals Sales Growth

Jim Cramer on Johnson & Johnson's Pharmaceuticals Sales Growth